SuperworthMira Pharmaceuticals EPS MIRA
Diluted earnings per share by quarter and over the last twelve months, from 2022.
- Last 12 months, to Jun 30, 2026
- −$1.39
- Latest quarter, Q2 FY26
- −$0.03
- Fiscal year 2025
- −$1.53
Mira Pharmaceuticals' earnings per share was −$1.39 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.03.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.53 | n/a |
| FY2024 | −$0.54 | n/a |
| FY2023 | −$0.63 | n/a |
| FY2022 | −$0.48 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.03 | n/a | −$1.39 | |
| Q1 FY26 | −$0.03 | n/a | −$1.45 | |
| Q4 FY25 | −$0.15 | n/a | −$1.53 | |
| Q3 FY25 | −$1.18 | n/a | −$1.52 | |
| Q2 FY25 | −$0.09 | n/a | −$0.48 | |
| Q1 FY25 | −$0.11 | n/a | −$0.50 | |
| Q4 FY24 | −$0.14 | n/a | −$0.54 | |
| Q3 FY24 | −$0.14 | n/a | −$0.57 | |
| Q2 FY24 | −$0.11 | n/a | −$0.69 | |
| Q1 FY24 | −$0.15 | n/a | −$0.68 | |
| Q4 FY23 | −$0.17 | n/a | −$0.63 | |
| Q3 FY23 | −$0.26 | n/a | −$0.50 |
Against its peers
Companies in Drug Manufacturers - General nearest Mira Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| MIRAMira Pharmaceuticals | −$1.39 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Mira Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.